# A comparison of transplant outcomes in peritoneal and hemodialysis patients

## JON J. SNYDER, BERTRAM L. KASISKE, DAVID T. GILBERTSON, and ALLAN J. COLLINS

_Minneapolis Medical Research Foundation, Minneapolis, Minnesota; Department of Medicine, Hennepin County Medical_
_Center, Minneapolis, Minnesota; and Department of Medicine, University of Minnesota, Minneapolis, Minnesota_

**A comparison of transplant outcomes in peritoneal and hemo-** The role of pre-transplant dialysis modality in affect**dialysis patients.** ing transplant outcomes has been the subject of long_Background. Studies examining the effect of pre-transplant_
standing interest. Recent studies have reported that peridialysis modality on graft and patient survival after kidney
transplantation have produced conflicting results. Therefore, toneal dialysis is associated with a lower incidence of
we studied the effects of pre-transplant dialysis modality on post-transplant delayed graft function (DGF) compared
outcomes in a large United States cohort. to hemodialysis [1–5]. On the other hand, there have
_Methods. We compared rates of transplantation between_ been reports that patients receiving peritoneal dialysis
peritoneal dialysis and hemodialysis patients from the years
are more likely to have graft thrombosis compared to
1995 to 1998 in the United States (N � 252,402) and outcomes
after transplantation (N � 22,776), using data from the Centers patients treated with hemodialysis [6–9]. Most previous
for Medicare and Medicaid Services. studies have reported that graft survival is not affected
_Results. In a Cox proportional hazards analysis that was ad-_ by the modality of dialysis treatment prior to transplantajusted for multiple patient characteristics, kidney transplantation
tion [2, 9–14]. However, many of these studies were
was 1.39 (95% CI � 1.35 to 1.43) times more likely in peritoneal
small, had a limited number of factors that were addialysis vs. hemodialysis patients (P � 0.0001). Over the entire
follow-up period, the adjusted risk for death-censored graft dressed in the analysis and may have lacked adequate
failure was 1.15 (1.04 to 1.26) times higher in peritoneal dialysis statistical power to determine whether dialysis treatment
vs. hemodialysis (P � 0.05), but mortality and overall graft modality is independently associated with graft survival.
failure rates were not different. Pre-transplant dialysis modality
Fundamental to assessing the relationship between didid not affect outcomes for patients who survived with a functioning kidney for at least 3 months. However, in adjusted Cox alysis modality and post-transplant outcomes is the likelianalyses restricted to the first 3 months, peritoneal dialysis was hood of receiving a renal transplant based on the choice
associated with a 1.23 (1.09 to 1.39) times higher risk for early of peritoneal dialysis or hemodialysis as the initial treatgraft failure (P � 0.001) and a 1.33 (1.16 to 1.53) times higher ment for end-stage renal disease (ESRD). Since the numrisk for death-censored graft failure (P � 0.001). Peritoneal
ber of factors that may be associated with the transplant
dialysis patients, however, were seen to have a lower incidence
of delayed graft function. In a smaller sample of patients with process are considerable, we chose to study a large cohort
data on causes of early graft failure, graft thrombosis was more of United States ESRD patients with information not
commonly listed as a cause of graft failure among peritoneal only on their dialysis treatment period but also their
dialysis patients, 41% (64/156), compared to hemodialysis paprofile of transplant donor and recipient characteristics.
tients, 30% (106/349), P � 0.05.
_Conclusions. Kidney transplantation is more frequent in peri-_ This report summarizes our finding from data supplied
toneal dialysis than in hemodialysis patients, and transplanta- by the United States Centers for Medicare and Medicaid
tion in peritoneal dialysis patients is more frequently associated Services (CMS).
with early, but not late, graft failure. Delayed graft function was
less common in peritoneal dialysis patients but this potential
benefit appears to be offset by other factors which are associated **METHODS**
with early graft loss. Additional studies are needed to determine
what factors may help understand this early risk of graft failure. **Patient population**

We included Medicare beneficiaries who (1) were 18
**Key words: kidney transplantation, delayed graft function, allograft** years old or older, (2) first started therapy for ESRD
survival, graft thrombosis. between 1995 and 1998, and (3) had been on the same
dialysis modality (hemodialysis or peritoneal dialysis)
Received for publication February 22, 2002
and in revised form April 19, 2002 for at least 60 days on day 90 of ESRD therapy [N �
Accepted for publication May 8, 2002 252,402; hemodialysis � 219,240 (87%); and peritoneal
 2002 by the International Society of Nephrology dialysis � 33,162 (13%)]. In our study of the effects of


-----

dialysis modality on outcomes after kidney transplanta- including death, and return to dialysis or re-transplant
tion, we included those patients described above who (death-censored graft failure). Models were adjusted for
received a kidney-only transplant and had no prior his- dialysis exposure time, dialysis modality switch (whether
tory of other organ transplantation (N � 22,776). a patient had switched modalities prior to transplantation), the year of transplantation, gender, race, age at time
**Analytical methods**
of transplantation, Hispanic ethnicity, body size (BSA),
To determine the relative likelihood of peritoneal dial- obesity (BMI of 30 kg/m[2] or more), baseline GFR, baseysis vs. hemodialysis patients to receive a kidney trans- line co-morbidity, education level, ability to work, human
plant, we used Cox proportional hazards analyses with
lymphocyte antigens (HLA) mismatches, donor type, dokidney transplantation occurring before November 30,
nor gender, donor age, donor race, panel reactive antibody
2000, as the end point. In two separate analyses we used
(PRA), and cold ischemia time. Due to non-proportionboth “intent-to-treat” based on dialysis modality on day
ality of the hazards over time, additional Cox models
90, and “on treatment” with patients censored at a change
were run on outcomes in the first 3 months post-transplant
in dialysis modality (change of at least 60 days) or if lost
and conditional graft loss following the first 3 months. All
to follow-up. For both of these analyses, patients were
analyses used SAS version 8.2 (Cary, NC, USA).
censored at death. These analyses were adjusted for age,
gender, race, Hispanic ethnicity, year of ESRD initiation,
body size measured as body surface area (BSA) calcu- **RESULTS**
lated from height and weight [15], obesity defined as
**Likelihood of transplantation**
body mass index (BMI) greater than 29 kg/m[2], estimated
During the follow-up period, a greater proportion of
baseline glomerular filtration rate (GFR) at dialysis initiation (as calculated from serum creatinine, age, gender, peritoneal dialysis vs. hemodialysis patients received a
and race), diabetes as primary cause of renal failure, kidney transplant (Fig. 1). By 1, 3, and 5 years after
ability to work, and baseline co-morbidities. Baseline starting dialysis for ESRD, the proportions of peritoneal
co-morbidities were determined from the CMS Medical dialysis and hemodialysis patients receiving a kidney
Evidence Form (Form 2728, End-Stage Renal Disease transplant (by Kaplan-Meier analysis) were 9.2% (95%
Medical Evidence Report Medicare Entitlement and/or CI � 8.8 to 9.5%) vs. 3.8% (3.7 to 3.9%), 23.6% (23.0
Patient Registration). Co-morbidities included cardio- to 24.1%) vs. 10.9% (10.7 to 11.0%), and 31.7% (30.9
vascular disease (congestive heart failure, ischemic heart to 32.6%) vs. 15.7% (15.5-16.0%), respectively. Simidisease, myocardial infarction, cardiac arrest, cardiac larly, in unadjusted Cox proportional hazards analysis,
dysrhythmia, and pericarditis), peripheral vascular dis- the relative likelihood of receiving a kidney transplant
ease (PVD), and hypertension. In the end, both the “in- was 2.34 (2.28 to 2.41, P � 0.0001) times greater for
tent-to-treat” and “on treatment” analyses gave similar peritoneal dialysis than for hemodialysis patients. Howresults, and therefore only the “intent-to-treat” results ever, most of this difference can be explained by differare presented. ences in the patients selected for peritoneal dialysis and
To determine the effect of pre-transplant dialysis mod- hemodialysis. Indeed, after adjustments were made for
ality on graft survival, three different approaches were
differences in peritoneal dialysis and hemodialysis paused: (1) the dialysis modality was determined on day
tients, the relative likelihood of receiving a kidney trans90 of ESRD care and patients were assumed to be on
plant was only 1.39 (1.35 to 1.43, P � 0.0001) times
this modality until the time of transplantation (similar
greater for peritoneal dialysis than for hemodialysis pato intent-to-treat); (2) for patients switching modality
tients (Table 1).
more the 60 days prior to transplantation and for a period
The difference in the likelihood of transplantation beof no less than 60 days, the new modality was taken as
tween peritoneal dialysis and hemodialysis patients does
the pre-transplant dialysis modality; and (3) the prenot appear to be a result of differences in the likelihood
transplant dialysis modality was determined from the
of making it to the waiting list for cadaveric renal transUnited Network for Organ Sharing (UNOS) Transplant
plantation. In this population, 87% of hemodialysis paRecipient Registration Form at the time of transplant.
tients were listed and 86% of peritoneal dialysis patients
In the event this information was missing from the UNOS
form, the last known modality based on Medicare data were listed (�[2] _P �_ 0.4669). When only considering pawas used. In the end, the results did not differ signifi- tients who received a cadaveric transplant, 99.8% of both
cantly between these three approaches, and therefore hemodialysis and peritoneal dialysis patients had been
only the results from the third approach are presented. listed (�[2] _P �_ 0.8018). Similarly, for patients who went
Separate Cox proportional hazards analyses were used on to receive a living donor transplant, 59% of both
to assess the relative risk of pre-transplant peritoneal hemodialysis and peritoneal dialysis patients had been
dialysis vs. hemodialysis on patient survival, graft failure, listed (�[2] _P �_ 0.9877).


-----

**Fig. 1. The percentages of new hemodialysis**
**(HD, solid line) and peritoneal dialysis (PD,**
**dashed line) patients who received a kidney**
**transplant by Kaplan-Meier analysis. Patients**
shown here were analyzed by intention-totreat, where a change in dialysis modality was
ignored.

**Table 1. Characteristics of peritoneal and hemodialysis patients that are associated with the relative likelihood of kidney transplantation**

Percent with characteristic
Likelihood of transplantation
Among PD Among HD
Characteristic patients % patients % RR (95% CI) _P value_

PD vs. HD — — 1.39 (1.35–1.43) �0.0001
Female gender 46 47 0.85 (0.82–0.87) �0.0001
Age years
18 to 19 5 3 Reference —
30 to 44 35 52 0.65 (0.63–0.68) �0.0001
45 to 64 41 34 0.32 (0.31–0.33) �0.0001
65� 18 11 0.03 (0.03–0.03) �0.0001
Race
Caucasian 65 52 Reference —
African American 21 32 0.34 (0.33–0.35) �0.0001
Other 14 15 0.56 (0.53–0.60) �0.0001
Hispanic ethnicity 9 11 1.03 (0.96–1.10) 0.4133
ESRD from diabetes 45 44 0.83 (0.81–0.86) �0.0001
Year of ESRD
1995 28 22 Reference —
1996 27 24 0.94 (0.90–0.97) 0.0006
1997 24 26 0.89 (0.85–0.92) �0.0001
1998 21 28 0.75 (0.72–0.79) �0.0001
Body Size (BSA)
Small (�1.7 m[2]) 26 30 0.92 (0.88–0.95) �0.0001
Medium (1.7 to 1.9 m[2]) 43 41 Reference —
Large (�1.9 m[2]) 31 29 1.08 (1.04–1.12) �0.0001
Obese (BMI �29 kg/m[2]) 18 20 0.68 (0.65–0.71) �0.0001
Baseline GFR mL/min
Low (�6.1) 27 28 1.04 (1.01–1.07) 0.0215
Intermediate (6.1 to 8.7) 46 43 Reference —
High (�8.7) 27 28 0.81 (0.78–0.84) �0.0001
Ability to work 49 48 1.66 (1.61–1.70) �0.0001
Co-morbidities
CVD 32 41 0.60 (0.58–0.63) �0.0001
PVD 11 13 0.61 (0.57–0.65) �0.0001
Hypertension 64 65 1.15 (1.12–1.19) �0.0001

Shown are the percent of pre-transplant PD (column 2, N � 33,162) and HD (column 3, N � 219,240) patients with characteristics in column 1, and the relative
likelihood of transplantation (columns 4 and 5). Abbreviations are: PD, peritoneal dialysis; HD, hemodialysis; RR, relative risk; CI, confidence interval; ESRD, endstage renal disease; BMI, body mass index; GFR, glomerular filtration rate; CVD, cardiovascular disease; PVD, peripheral vascular disease.

**Transplant outcomes** vs. hemodialysis (Fig. 2A), death-censored graft failure
Pre-transplant dialysis modality was associated with was more frequent for peritoneal dialysis vs. hemodialydifferences in outcomes after transplantation. There sis patients (Fig. 2C), and there was no difference in
were 5621 (25%) patients on peritoneal dialysis and overall graft failure in patients treated with peritoneal
17,155 (75%) patients on hemodialysis prior to trans- dialysis vs. hemodialysis (Fig. 2B). However, using a Cox
plantation. In unadjusted (Kaplan-Meier) analysis, mor- proportional hazards model to adjust for multiple risk
tality was less for those treated with peritoneal dialysis factors, peritoneal dialysis patients had similar rates of


-----

**Fig. 2. Unadjusted (Kaplan-Meier) outcomes**
**comparing transplant recipients treated with**
**either peritoneal dialysis (PD, gray line) or**
**hemodialysis (HD, black line) pre-transplant.**
Shown are mortality (A), graft failure due to
death, return to dialysis or re-transplantation
(B), or death-censored graft failure due to
dialysis or re-transplantation (C ). Log rank,
_P �_ 0.001; Wilcoxon, P � 0.0002.

death and graft failure, but a 15% increased risk of death- plant. Data on the cause of graft failure were available
censored graft failure (Table 2). for only 1030 (33%) of hemodialysis patients and 401
Most of the risk attributable to pre-transplant dialysis (38%) of peritoneal dialysis patients on the UNOS transmodality was manifest in the first 3 months following plant recipient and follow-up forms. Of all of the causes
transplantation (Fig. 2 B and C). In Cox proportional examined, only graft thrombosis was more frequent in
hazards analyses adjusted for multiple risk factors, but peritoneal dialysis vs. hemodialysis patients [odds ratio �
restricted to the first 3 months of follow-up, peritoneal 1.59 (1.08 to 2.36), P � 0.0192, Table 4].
dialysis was clearly associated with a higher risk for graft
failure and death-censored graft failure, but not mortal- **Delayed graft function**
ity (Table 3). On the other hand, in adjusted Cox analyses We used logistic regression analysis to examine the
that included only patients whose grafts functioned for associated role of dialysis modality on the incidence of
at least 3 months, there was little effect of dialysis mod- delayed graft function (DGF), defined by the need for
ality on outcomes, emphasizing that the increased risk dialysis during the first week after transplantation.
in the peritoneal dialysis population occurs early in the Among hemodialysis patients, 16% of patients had DGF,
post-transplant period (Table 3). while only 12% of peritoneal dialysis patients had DGF.
The cause of graft failure was investigated for patients Pre-transplant peritoneal dialysis was associated with a
whose grafts failed within the first 3 months post-trans- lower risk for DGF, with the odds ratio (peritoneal dial

-----

**Table 2. Effects of pre-transplant dialysis modality and other factors on outcomes after kidney transplantation**

Relative risk (95% CI)

Death-censored
Characteristics Graft failure graft failure Death

PD vs. HD 1.05 (0.97–1.13) 1.15 (1.04–1.26)[a] 0.95 (0.85–1.06)
Dialysis duration months 1.00 (0.99–1.00) 0.98 (0.98–0.99)[c] 1.02 (1.01–1.02)[c]
Changed dialysis modality 1.02 (0.90–1.14) 1.00 (0.85–1.17) 1.06 (0.90–1.24)
Transplant era
1995–1996 Reference Reference Reference
1997–1998 0.68 (0.63–0.74)[c] 0.56 (0.50–0.62)[c] 0.86 (0.76–0.98)[a]
1999–2000 0.82 (0.73–0.93)[a] 0.83 (0.72–0.97)[a] 0.78 (0.64–0.94)[a]
Female (vs. male) 1.08 (1.00–1.16)[a] 1.10 (1.00–1.21) 1.06 (0.95–1.17)
Age years
18 to 29 Reference Reference Reference
30 to 44 0.90 (0.80–1.01) 0.82 (0.72–0.93)[a] 1.39 (1.09–1.77)[a]
45 to 64 1.11 (1.00–1.24) 0.73 (0.64–0.83)[c] 2.87 (2.28–3.60)[c]
65� 1.51 (1.32–1.74)[c] 0.64 (0.53–0.78)[c] 5.14 (4.02–6.58)[c]
Race
Caucasian Reference Reference Reference
African American 1.03 (0.95–1.12) 1.19 (1.06–1.33)[a] 0.84 (0.75–0.95)[a]
Other 0.73 (0.62–0.86) 0.76 (0.61–0.95)[a] 0.66 (0.52–0.84)[b]
Hispanic ethnicity 1.04 (0.86–1.25) 1.15 (0.90–1.48) 0.93 (0.70–1.22)
ESRD from diabetes 1.13 (1.05–1.22)[b] 0.80 (0.72–0.89)[c] 1.65 (1.50–1.82)[c]
Body size (BSA)
Small (�1.7 m[2]) 1.03 (0.94–1.13) 0.99 (0.87–1.12) 1.11 (0.97–1.26)
Medium (1.7 to 1.9 m[2]) Reference Reference Reference
Large (�1.9 m[2]) 1.01 (0.93–1.10) 1.08 (0.96–1.21) 0.91 (0.80–1.03)
Obese (BMI �29 kg/m[2]) 1.00 (0.91–1.10) 0.95 (0.84–1.09) 1.06 (0.93–1.22)
Baseline GFR mL/min
Low (�6.1) 0.94 (0.88–1.02) 0.97 (0.88–1.07) 0.90 (0.80–1.00)
Intermediate (6.1 to 8.7) Reference Reference Reference
High (�8.7) 1.13 (1.03–1.25)[a] 1.14 (1.00–1.30) 1.14 (1.00–1.31)[a]
Co-morbidities
CVD 1.11 (1.02–1.21)[a] 0.90 (0.78–1.03) 1.32 (1.17–1.48)[c]
PVD 1.21 (1.04–1.41)[a] 1.06 (0.83–1.36) 1.31 (1.09–1.58)[a]
Hypertension 0.94 (0.87–1.01) 0.92 (0.84–1.01) 0.95 (0.86–1.06)
HLA mismatches
0 0.85 (0.76–0.95)[a] 0.89 (0.76–1.03) 0.82 (0.70–0.96)[a]
1 0.98 (0.83–1.15) 0.95 (0.76–1.18) 1.03 (0.83–1.29)
2 0.91 (0.82–1.02) 0.98 (0.85–1.13) 0.89 (0.76–1.04)
3 Reference Reference Reference
4 1.10 (0.99–1.21) 1.19 (1.04–1.36)[a] 0.98 (0.85–1.13)
5 1.13 (1.01–1.26)[a] 1.16 (1.00–1.34)[a] 1.10 (0.94–1.28)
6 1.27 (1.10–1.46)[b] 1.33 (1.10–1.60)[a] 1.23 (1.02–1.50)[a]
Living donor 0.88 (0.79–0.98)[a] 0.98 (0.86–1.13) 0.71 (0.60–0.83)[c]
Female donor 1.08 (1.01–1.15)[a] 1.09 (1.00–1.19)[a] 1.03 (0.94–1.13)
Donor age years
0 to 17 0.96 (0.84–1.10) 1.07 (0.90–1.27) 0.91 (0.75–1.09)
18 to 29 Reference Reference Reference
30 to 44 1.10 (1.00–1.22) 1.12 (0.98–1.29) 1.09 (0.94–1.26)
45 to 64 1.41 (1.28–1.56)[c] 1.51 (1.32–1.72)[c] 1.37 (1.19–1.57)[c]
65� 1.99 (1.69–2.34)[c] 2.43 (1.95–3.04)[c] 1.84 (1.49–2.28)[c]
Donor race
Caucasian Reference Reference Reference
African American 1.24 (1.11–1.37)[c] 1.21 (1.05–1.39)[a] 1.30 (1.11–1.51)[b]
Other 0.96 (0.83–1.10) 0.95 (0.79–1.14) 0.96 (0.78–1.18)
PRA �50% 1.20 (0.97–1.48) 1.32 (1.01–1.74)[a] 1.13 (0.84–1.53)
Cold ischemia time hours
0 Reference Reference Reference
1 to 12 1.20 (1.03–1.40)[a] 1.31 (1.07–1.61)[a] 0.96 (0.76–1.20)
13 to 24 1.43 (1.20–1.71)[c] 1.62 (1.29–2.05)[c] 1.05 (0.81–1.36)
25� 1.43 (1.19–1.71)[b] 1.73 (1.36–2.19)[c] 1.02 (0.79–1.33)
College educated 0.88 (0.80–0.97)[a] 0.89 (0.78–1.01) 0.86 (0.75–0.99)[a]
Ability to work 0.92 (0.85–0.99)[a] 0.98 (0.89–1.09) 0.80 (0.71–0.89)[c]

Abbreviations are: PD, peritoneal dialysis; HD, hemodialysis; ESRD, end-stage renal disease; BSA, body surface area; BMI, body mass index; GFR, glomerular
filtration rate; CVD, cardiovascular disease; PVD, peripheral vascular disease; HLA, human leukocyte antigen; PRA, panel reactive antibody.
a _P �_ 0.05; b _P �_ 0.001; c _P �_ 0.0001


-----

**Table 3. Effects of pre-transplant dialysis modality on outcomes early vs. late after kidney transplantation**

Relative risk (95% CI) PD:HD

Death-censored
Post-transplant period Graft failure graft failure Death

During the first 3 months 1.23 (1.09–1.39)[a] 1.33 (1.16–1.53)[b] 1.03 (0.81–1.30)
Beyond the first 3 months 0.96 (0.87–1.05) 1.02 (0.89–1.16) 0.91 (0.80–1.04)

Results of Cox proportional hazards analyses (adjusted for covariates in Table 2) during the first 3 months after transplantation and beyond the first 3 months
after transplantation (among those patients who survived with functioning grafts for at least 3 months).
a _P �_ 0.001; b _P �_ 0.0001

**Table 4. Causes of graft failure (primary or contributing) for patients whose graft failed within the first 3 months[a]**

Percent with characteristic

Cause Among PD patients (%, N ) Among HD patients (%, N ) _P value[b]_

Hyperacute rejection[c] 3 (3/95) 4 (7/195) 1.0000
Surgical complications[c] 3 (3/95) 6 (11/195) 0.5602
Acute rejection[d] 27 (42/156) 27 (95/349) 0.9446
Primary failure[d] 13 (21/156) 15 (52/349) 0.6711
Graft thrombosis[d] 41 (64/156) 30 (106/349) 0.0192
Infection[d] 8 (12/156) 10 (34/349) 0.4595
Urological complications[d] 2 (3/156) 2 (7/349) 1.0000
Recurrent disease[d] 3 (4/156) 2 (6/349) 0.5071
Other[d] 15 (23/156) 19 (66/349) 0.2561

a Patients may have more than one cause of graft failure
b _P value from Fisher’s exact test (when fewer than five expected events) or Chi-square test_
c For patients whose graft failed immediately
d For patients whose graft failed immediately or after discharge

ysis:hemodialysis) for DGF being 0.74 (0.67 to 0.81, P � plant compared to hemodialysis patients. While many
0.0001) after adjustment for multiple covariates. For pa- of the factors associated with increased transplant utilizatients whose graft survived at least 7 days, DGF was tion may be more represented in the peritoneal dialysis
associated with a 2.8 (2.2 to 3.6, P � 0.0001) times greater population, the difference in transplant utilization perrisk of death, a 2.9 (2.6 to 3.4, P � 0.0001) times greater sisted after adjusting the analysis for differences in parisk of graft failure, and a 2.9 (2.5 to 3.5, P � 0.0001) times tient characteristics (Table 1). There may be a perception
greater risk of death-censored graft failure, regardless of among patients and their physicians that peritoneal dialpre-transplant dialytic modality. The observed increased ysis is the dialysis treatment modality of choice for transrisk of graft failure and death-censored graft failure in plant candidates [3, 17]. If placement of a peritoneal
the peritoneal dialysis population in the first 3 months dialysis catheter is thought to cause less morbidity and
post-transplant is present despite the apparent beneficial mortality than placement of a hemodialysis access, then
effects of a lower incidence of DGF in the peritoneal peritoneal dialysis may be selected more often than hedialysis population. modialysis when it is perceived to be a better short-term
bridge to kidney transplantation. On the other hand, if
there is a perception that hemodialysis offers better long**DISCUSSION**
term dialysis treatment, then patients less likely to unIn our analysis, peritoneal patients were approxi- dergo transplantation may be selected for hemodialysis
mately 50% more likely to undergo kidney transplanta- more often than peritoneal dialysis. In any case, it is
tion compared to hemodialysis patients. Few others have plausible that the observed difference in the likelihood
compared the rates of transplantation for peritoneal and for peritoneal dialysis vs. hemodialysis patients to receive
hemodialysis patients. More than a decade ago, Held et a kidney transplant could be due to a selection bias,
al found that the rate of transplantation among 3393 whereby transplant candidates were more likely to be
children was similar, albeit slightly higher, for peritoneal placed on peritoneal dialysis than hemodialysis.
dialysis vs. hemodialysis patients [16]. These investiga- An important and surprising finding in this study is
tors did not examine the rates of transplantation among the higher rate of early graft failure in peritoneal dialysis
adult peritoneal dialysis and hemodialysis patients. compared to hemodialysis patients even after adjusting
We cannot discern from our analysis why peritoneal for multiple patient characteristics that may also infludialysis patients were more likely to receive a kidney trans- ence outcomes. Most other studies have reported that


-----

pre-transplant dialysis modality has no effect on patient vs. hemodialysis patients is the possibility that residual
or graft survival [2, 9–14]. Similarly, most investigators native kidney function is better preserved in peritoneal
found no difference in the rates of acute rejection in dialysis than in hemodialysis [22–24]. The reduced early
peritoneal dialysis vs. hemodialysis [2, 4, 9, 13]. However, graft survival associated with peritoneal dialysis comVanholder et al reported a greater number of peritoneal pared to hemodialysis is all the more remarkable given the
dialysis patients developed acute rejection after trans- lower incidence of DGF in peritoneal dialysis patients.
plantation compared to hemodialysis [3]. Most of these We attempted to determine which dialysis modality
studies were smaller than the current investigation, and patients with DGF were treated with by searching Medithe investigators did not separately examine the effects care Part B claims within 1 month of the transplant date.
of dialysis modality on short-term and long-term graft In this study population, DGF was indicated for 3533
survival. This is an important issue since the hazard func- patients. Claims could only be reliably searched for 2626
tions are not proportional over time. As a result, it is of these patients for whom Medicare appeared to be
not surprising that others did not find the association the primary payer. Of these patients, we were able to
between dialysis modality and early graft failure that we determine which modality patients were treated with
report here. for 1925 (73%) patients. For the 351 peritoneal dialysis
We could not determine how pre-transplant dialysis patients, 166 (47%) were treated with peritoneal dialysis
modality influenced early post-transplant graft failure. following transplantation. In the 1574 hemodialysis paThe result seems unlikely to be explained by a higher tients, 1551 (99%) were treated with hemodialysis folrate of infection in peritoneal dialysis patients, since this lowing transplantation. These differences suggest it is
would be expected to have a greater effect on mortality possible that the effects of pre-transplant dialysis modthan death-censored graft failure. In addition, previous ality on early graft failure may have been influenced by
studies comparing the rates of post-transplant infections the effects of dialysis modality during DGF. Few studies
between peritoneal dialysis and hemodialysis patients have examined the effects of dialysis modality on the
have produced conflicting results. Passalacqua et al found pharmacokinetics of immunosuppressive agents. In a rea higher incidence of infection in the first 30 days post- cent study, the active metabolite of mycophenolate motransplant, and this higher rate of infection was associ- fetil, mycophenolic acid, was found to be readily removed
ated with rejection and longer hospital stays [18]. Binaut by peritoneal dialysis [25]. Thus, it is possible that rejecet al reported no overall difference in bacterial infec- tion rates in patients with DGF could be indirectly influtions, but a higher rate of sepsis was seen in peritoneal enced by pre-transplant dialysis modality, if levels of
dialysis vs. hemodialysis patients [2]. Others have found immunosuppressive medications are altered. More work
no difference in the rate of post-transplant infections in in this area is needed to determine the possible risk factors
peritoneal vs. hemodialysis patients [3, 19]. Still others and the associated complications post-transplant that
have reported that hemodialysis patients have a higher may be amenable to interventions.
rate of infections after transplantation [20]. Thus, it
seems unlikely that a higher rate of infection in perito**CONCLUSION**
neal dialysis patients could explain the association between dialysis modality and early graft failure. In summary, this analysis demonstrated that the rate
In a subset of about one third of patients with data of transplantation is higher in patients treated with perion the cause of graft failure, graft thrombosis was more toneal dialysis compared to patients treated with hemocommon in peritoneal dialysis vs. hemodialysis patients dialysis, and this difference could not be entirely explained
(Table 4). Graft thrombosis has also been reported by by differences in the two patient populations. Interestothers to be more common in peritoneal dialysis vs. ingly, the rate of early, but not late, graft failure was higher
hemodialysis patients [6–9]. Indeed, we found only one in patients treated with peritoneal dialysis compared to
study that examined the incidence of graft thrombosis hemodialysis prior to transplantation. Although we canand failed to find a difference in peritoneal dialysis vs. not determine the cause of this associated higher rate
hemodialysis patients [21]. Thus, it is likely that early of graft failure, an analysis of a subset of patients with
graft thrombosis contributed to the higher rate of early data on the cause of graft failure suggested that a higher
graft failure associated with pre-transplant peritoneal rate of graft thrombosis might have contributed. Addidialysis. However, our results should be interpreted cau- tional studies are needed to better understand the slightly
tiously, given that the large proportion of missing data higher rate of early graft failure in the peritoneal dialysis
on the cause of graft failure could bias the results. population.
We found that DGF is less common in patients treated
with peritoneal dialysis vs. hemodialysis pre-transplant. **ACKNOWLEDGMENT**
This finding is consistent with those of others [1–5]. One This work was supported by an unrestricted grant from Baxter
explanation for a lower rate of DGF in peritoneal dialysis International, Inc. and the Minneapolis Medical Research Foundation.


-----

_Reprint requests to Jon J. Snyder, M.S., Minneapolis Medical Research_ tory peritoneal dialysis and renal transplantation: A ten-year expe_Foundation, 914 S. 8[th]_ _St. Suite D-253, Minneapolis, MN 55404, USA._ rience in a single center. Peritoneal Dial Int 12:242–249, 1992
_Email: jsnyder@nephrology.org_ 13. Cacciarelli TV, Sumrani NB, Dibenedetto A, et al: The influence of mode of dialysis pretransplantation on long-term renal allograft outcome. Ren Fail 15:545–550, 1993
**REFERENCES** 14. Cosio FG, Alamir A, Yim S, et al: Patient survival after renal
1. Perez FM, Rodriguez-Carmona A, Bouza P, et al: Delayed graft transplantation: I. The impact of dialysis pre-transplant. Kidney
function after renal transplantation in patients undergoing perito- _Int 53:767–772, 1998_
neal dialysis and hemodialysis. Adv Perit Dial 12:101–104, 1996 15. Du Bois D, Du Bois EF: A formula to estimate the approximate
2. Binaut R, Hazzan M, Pruvot FR, et al: Comparative study of surface area if height and weight are known. Arch Intern Med 17:
chronic ambulatory peritoneal dialysis versus hemodialysis patients 863–871, 1916
after kidney transplantation: clinical and financial assessment. 16. Held PJ, Turenne MN, Liska DW, et al: Treatment modality
_Transplant Proc 29:2428, 1997_ patterns and transplantation among the United States pediatric
end-stage renal disease population: a longitudinal study. Clin Trans3. Vanholder R, Heering P, Loo AV, et al: Reduced incidence of
_plant 71–85, 1991_
acute renal graft failure in patients treated with peritoneal dialysis
17. Thodis E, Passadakis P, Vargemezis V, Oreopoulos DG: Peritocompared with hemodialysis. Am J Kidney Dis 33:934–940, 1999
neal dialysis: Better than, equal to, or worse than hemodialysis?
4. Bleyer AJ, Burkart JM, Russell GB, Adams PL: Dialysis modData worth knowing before choosing a dialysis modality. Peritoneal
ality and delayed graft function after cadaveric renal transplanta_Dial Int 21:25–35, 2001_
tion. J Am Soc Nephrol 10:154–159, 1999
18. Passalacqua JA, Wiland AM, Fink JC, et al: Increased incidence
5. Van Biesen W, Vanholder R, Van Loo A, et al: Peritoneal dialysis
of postoperative infections associated with peritoneal dialysis in
favorably influences early graft function after renal transplantation
renal transplant recipients. Transplantation 68:535–540, 1999
compared to hemodialysis. Transplantation 69:508–514, 2000
19. Kang Z, Fang G, Chen W: A comparative study of the outcome
6. Murphy BG, Hill CM, Middleton D, et al: Increased renal alloof renal transplantation in peritoneal dialysis and hemodialysis
graft thrombosis in CAPD patients. Nephrol Dial Transplant 9:
patients. Chin Med Sci J 7:49–52, 1992
1166–1169, 1994
20. Miemois-Foley J, Paunio M, Lyytikainen O, Salmela K: Bac7. van der Vliet JA, Barendregt WB, Hoitsma AJ, Buskens FG:
teremia among kidney transplant recipients: A case-control study
Increased incidence of renal allograft thrombosis after continuous
of risk factors and short-term outcomes. Scand J Infect Dis 32:69–
ambulatory peritoneal dialysis. Clin Transplant 10:51–54, 1996 73, 2000
8. Ojo AO, Hanson JA, Wolfe RA, et al: Dialysis modality and the 21. Perez Fontan M, Rodriguez-Carmona A: Garcia FT, et al:
risk of allograft thrombosis in adult renal transplant recipients. Peritoneal dialysis is not a risk factor for primary vascular graft
_Kidney Int 55:1952–1960, 1999_ thrombosis after renal transplantation. Peritoneal Dial Int 18:311–
9. Vats AN, Donaldson L, Fine RN, Chavers BM: Pretransplant 316, 1998
dialysis status and outcome of renal transplantation in North 22. Rottembourg J, Allouache M, Issad B, et al: Outcome and folAmerican children: A NAPRTCS Study. North American Pedi- low-up on CAPD. Contrib Nephrol 89:16–27, 1991
atric Renal Transplant Cooperative Study. Transplantation 69: 23. Lysaght MJ, Vonesh EF, Gotch F, et al: The influence of dialysis
1414–1419, 2000 treatment modality on the decline on remaining renal function.
10. Evangelista JB, Jr, Bennett-Jones D, Cameron JS, et al: Renal _ASAIO Trans 37:598–604, 1991_
transplantation in patients treated with haemodialysis and short 24. Misra M, Vonesh E, Van Stone JC, et al: Effect of cause and
term and long term continuous ambulatory peritoneal dialysis. Br time of dropout on the residual GFR: A comparative analaysis of
_Med J (Clin Res Ed) 291:1004–1007, 1985_ the decline of GFR on dialysis. Kidney Int 59:754–763, 2001
11. Rubin J, Kirchner KA, Raju S, et al: CAPD patients as renal 25. Morgera S, Neumayer HH, Fritsche L, et al: Pharmacokinetics of
transplant patients. Am J Med Sci 294:175–180, 1987 mycophenolate mofetil in renal transplant recipients on peritoneal
12. O’Donoghue D, Manos J, Pearson R, et al: Continuous ambula- dialysis. Int J Clin Pharmacol Ther 36:159–163, 1998


-----

